3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- Karmanos Cancer Institute, Wayne State University
Detroit, Michigan, United States
- Urology Cancer Center and Gu Research Network
Omaha, Nebraska, United States
- Memoral Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
- Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States
- Memorial Sloan Kettering West Harrison
Harrison, New York, United States
- Northshore University Health System
Long Island City, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Weill Cornell Medical Center
New York, New York, United States
- Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States
- Memoral Sloan Kettering Cancer Center at Phelps
Sleepy Hollow, New York, United States
- University of North Carolina
Chapel Hill, North Carolina, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Oregon Health & Science University Knight Cancer Institute
Portland, Oregon, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Dec 2012
- Primary completion
- 28 Sept 2020
- Completion
- 28 Sept 2020
- Last update posted
- 19 Nov 2021
- Registered enrollment
- 124
- Registry id
- NCT01751451
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.